Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No additional AE; Consumer reports she received her first dose of GARDASIL 9 in February of this year and has not had her second dose yet. No adverse effects reported. No other information provided. No additional AE. No PQC.; This spontaneous report was received from a patient and refers to a female patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown day in February 2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (lot # and expiration date were not reported) as prophylaxis. At the time of the report, she had not received her second dose yet (inappropriate schedule of product administration). No adverse effects were reported. No other information was provided. No additional adverse event was reported.